



Attorney Docket: 27099U
Date: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

VENNEMANN, et al.

Appl. No.: 10/562,149✓

Filed: December 23, 2005

For: NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF
CANCER

Art Unit: 1614

Examiner: Unknown

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 18 cited References, with copies for 17 of the 18 cited References.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

GMN/SMM/le



Attorney Docket: 27099U
Date: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

VENNEMANN, et al.

Appl. No.: 10/562,149

Filed: December 23, 2005

For: **NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

[XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113,

or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

GMN/SMM/le

O P E I P A S A FORM PTO-1449 APR 13 2006 INFORMATION DISCLOSURE CITATION		In re Application of: VENNEMANN, et al.		Art Unit: 1614
		Appl. No: 10/562,149	Filed: December 23, 2005	Examiner: Unknown

U. S. PATENT DOCUMENTS					
Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed	
/R.D./	A1 5,965,575	12 Oct. 1999	Peglion et al.	27 Mar. 1998	
	A2				
	A3				
	A4				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Translation
/R.D./	A5 97/28131 A1	7 Aug. 1997	WO	Abstract
/R.D./	A6 98/55118 A2	10 Dec. 1998	WO	N/A
/R.D./	A7 02/48144 A1	20 Jun. 2002	WO	N/A
/R.D./	A8 03/014115 A1	20 Feb. 2003	WO	N/A
/R.D./	A9 03/014116 A1	20 Feb. 2003	WO	N/A

OTHER

Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)	
/R.D./	Ashton, M.J., et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues", <u>J. Med. Chem.</u> , vol. 37, pp. 1696-1703, (1994).	
/R.D./	Benovsky, P., et al., "Aza-Annulation as a Versatile Approach to the Synthesis of Non-Benzodiazepene Compounds for the Treatment of Sleep Disorders", <u>Tetrahedron Letters</u> , vol. 38, no. 49, pp. 8475-8478, (1997).	
/R.D./	Díaz, M., et al., "Syntheses of Lamellarins I and K by [3+2] Cycloaddition of a Nitrone to an Alkyne", <u>Synlett</u> , no. 7, pp. 1164-1166, (2001).	
/R.D./	Govindachari, T.R., et al., "Application of the Bruckner Method to the Synthesis of Phenanthridine Derivatives", <u>J. Chem. Soc.</u> , pp. 4280-4283, (1956).	
/R.D./	Hershenson, F.M., "Synthesis of Ring-Fused Pyrroles. II. 1,3-Dipolar Cycloaddition Reactions of Munchnone Derivatives Obtained from Tetrahydroisoquinoline-1-carboxylic Acids", <u>J. Org. Chem.</u> , vol. 40, no. 6, (1975).	
/R.D./	Meyer, H., "Pyrrole durch cyclisierende Michael-Addition von Enaminen", <u>Liebigs Ann. Chem.</u> , pp. 1534-1544, (1981). (ABSTRACT)	
Examiner	/Rita Desai/	Date Considered 05/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		In re Application of: VENNEMANN, et al.	Art Unit: 1614
INFORMATION DISCLOSURE CITATION		Appl. No: 10/562,149	Filed: December 23, 2005
		Appl. No: 10/562,149	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
A16				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Translation
A17	03/014117 A1	20 Feb. 2003	WO	N/A
A18	03/051877 A1	26 Jun. 2003	WO	N/A
A19	03/093499 A2	13 Nov. 2003	WO	N/A
A20	2005/002579 A1	13 Jan. 2005	WO	N/A
A21	2005/003129 A1	13 Jan. 2005	WO	N/A
A22				
A23				
A24				

OTHER

Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)	
/R.D./	A25	Shepard, E.R., et al., "Preparation of Some Analogs of Papaverine", <u>J. Org. Chem.</u> , vol. 17, pp. 568-576, (1952).
	A26	
	A27	
	A28	
	A29	
	A30	

Examiner	Date Considered
/Rita Desai/	05/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.